UroGen Pharma (URGN) announced that Chris Degnan has been appointed CFO. Degnan succeeds Don Kim, who is leaving UroGen to pursue other opportunities. Degnan joins UroGen with extensive experience as a publicly traded biotech CFO, most recently at Galera Therapeutics (GRTX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN: